Skip to content

US · ANRO · BIOTECHNOLOGY

Alto Neuroscience, Inc. (ANRO) intrinsic value and stock valuation

$25.37as of 2026-11-21 · Mkt cap 983.68M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alto Neuroscience, Inc. DCF and intrinsic value

InvestorsCraft values ANRO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANRO’s statements →

Alto Neuroscience, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Mountain View, CA 94041 altoneuroscience.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-63.24M
20212025
Free cash flow
-$-51.79M
20212025
Total equity
$151.1M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$210K
Operating income-$-66.36M-$-68.61M-$-37.81M-$-29.19M-$-12.06M
Net income-$-63.24M-$-61.43M-$-36.3M-$-27.71M-$-9.19M
EPSd-$-2.19M-$-2.5M-$-1.35M-$-1.08M-$-359.41K
Operating cash flow-$-51.77M-$-47.42M-$-33.45M-$-20.39M-$-9.26M
Capital expenditure-$-20K-$-2.08M-$-470K-$-730K-$-680K
Free cash flow-$-51.79M-$-49.5M-$-33.92M-$-21.13M-$-9.94M
Total assets$184.7M$177.5M$86.6M$50.9M$28.8M
Total debt$4.41M$16.9M$9.99M$82.1M$38.2M
Net debt-$-172.08M-$-151.28M-$-72.56M$33.8M$12.5M
Total equity$151.1M$151.5M-$-71.67M-$-38.41M-$-12.48M
Cash and short-term investments$176.5M$168.2M$82.6M$48.3M$25.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$210K
Cost of revenue$660K$500K$0.00$340K$140K
Gross profit-$-660K-$-500K$0.00-$-340K$70K
Research and development expenses$45.6M$47M$30.3M$23.7M$8.37M
Selling, general and administrative expenses$20.8M$21.6M$7.52M$5.16M$3.75M
Other expenses-$-660K-$-500K$0.00$0.00$0.00
Operating expenses$65.7M$68.1M$37.8M$28.9M$12.1M
Cost and expenses$66.4M$68.6M$37.8M$29.2M$12.3M
Interest income$6.6M$8.85M$2.35M$110K$0.00
Interest expense$2.47M-$-1.38M$1.37M$0.00$0.00
Depreciation and amortization$660K$500K$370K$340K$140K
Ebitda-$-60.11M-$-62.3M-$-34.56M-$-27.37M-$-9.04M
Operating income-$-66.36M-$-68.61M-$-37.81M-$-29.19M-$-12.06M
Total other income/expenses, net$3.13M$7.18M$1.5M$1.48M$2.87M
Income before tax-$-63.24M-$-61.43M-$-36.3M-$-27.71M-$-9.19M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-63.24M-$-61.43M-$-36.3M-$-27.71M-$-9.19M
Weighted average shares outstanding$28.9M$24.6M$26.9M$25.6M$25.6M
Weighted average diluted shares outstanding$28.9M$24.6M$26.9M$25.6M$25.6M
Balance sheet
20252024202320222021
Cash and short-term investments$176.5M$168.2M$82.6M$48.3M$25.7M
Net receivables$0.00$0.00$10K$550K$1.74M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$177.7M$169.3M$85.4M$49.2M$27.7M
Property, plant and equipment, net$6.13M$7.7M$1.11M$1.58M$1.06M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$500K$500K$0.00$0.00$0.00
Total non-current assets$6.97M$8.21M$1.24M$1.63M$1.11M
Total assets$184.7M$177.5M$86.6M$50.9M$28.8M
Accounts payable$1.88M$1.58M$1.07M$1.61M$600K
Short-term debt$580K$870K$120K$280K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.3M$10M$5.61M$5.56M$1.81M
Long-term debt$3.82M$16.1M$9.86M$81.8M$38.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.2M$16.1M$152.7M$83.7M$39.5M
Capital lease obligations$0.00$5.39M$120K$120K$0.00
Total liabilities$33.6M$26.1M$158.3M$89.3M$41.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-201.63M-$-138.4M-$-76.97M-$-40.66M-$-12.95M
Accumulated other comprehensive income (loss)$20K-$-100K-$-80K-$-50K-$-20K
Total equity$151.1M$151.5M-$-71.67M-$-38.41M-$-12.48M
Total investments$500K$500K$0.00$0.00$0.00
Total debt$4.41M$16.9M$9.99M$82.1M$38.2M
Net debt-$-172.08M-$-151.28M-$-72.56M$33.8M$12.5M
Cash flow statement
20252024202320222021
Net income-$-63.24M-$-61.43M-$-36.3M-$-27.71M-$-9.19M
Depreciation and amortization$660K$500K$370K$340K$140K
Stock-based compensation$8.11M$7.63M$2.89M$1.76M$230K
Change in working capital$30K$4.06M-$-700K$4.58M-$-570K
Accounts receivable$0.00$0.00$330K$1.16M-$-1.28M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$220K$520K-$-630K$1.01M$460K
Net cash provided by operating activities-$-51.77M-$-47.42M-$-33.45M-$-20.39M-$-9.26M
Investments in property, plant and equipment-$-20K-$-2.08M-$-470K-$-730K-$-680K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$-2.08M-$-470K-$-730K-$-680K
Common stock issued$50.7M$137.6M$180K$40K$10K
Common stock repurchased-$-170K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$60.1M$135.7M$68.1M$43.8M$31.7M
Net change in cash$8.26M$86.2M$34.2M$22.6M$21.7M
Cash at end of period$177M$168.7M$82.6M$48.3M$25.7M
Operating cash flow-$-51.77M-$-47.42M-$-33.45M-$-20.39M-$-9.26M
Capital expenditure-$-20K-$-2.08M-$-470K-$-730K-$-680K
Free cash flow-$-51.79M-$-49.5M-$-33.92M-$-21.13M-$-9.94M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alto Neuroscience, Inc.

        Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

        CEO
        Amit Etkin
        Employees
        68
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Alto Neuroscience, Inc. (ANRO)?

        InvestorsCraft does not currently publish an intrinsic value for ANRO. How the IC value is calculated.

        Is ANRO undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANRO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.